These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 35093196)

  • 1. Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions.
    Al-Hassany L; Goadsby PJ; Danser AHJ; MaassenVanDenBrink A
    Lancet Neurol; 2022 Mar; 21(3):284-294. PubMed ID: 35093196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.
    Maasumi K; Michael RL; Rapoport AM
    Drugs; 2018 Jun; 78(9):913-928. PubMed ID: 29869205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC; Schwedt TJ
    Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale.
    Cohen F; Yuan H; Silberstein SD
    BioDrugs; 2022 May; 36(3):341-358. PubMed ID: 35476215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
    Porreca F; Navratilova E; Hirman J; van den Brink AM; Lipton RB; Dodick DW
    Cephalalgia; 2024 Mar; 44(3):3331024241238153. PubMed ID: 38477313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New drugs targeting calcitonin gene-related peptide for the management of migraines.
    Tana C; Cipollone F; Giamberardino MA; Martelletti P
    Expert Opin Emerg Drugs; 2023 Dec; 28(4):233-240. PubMed ID: 37996401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future prophylactic treatments in migraine: Beyond anti-CGRP monoclonal antibodies and gepants.
    Do TP; Al-Saoudi A; Ashina M
    Rev Neurol (Paris); 2021 Sep; 177(7):827-833. PubMed ID: 34294458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CGRP-targeted medication in chronic migraine - systematic review.
    Oliveira R; Gil-Gouveia R; Puledda F
    J Headache Pain; 2024 Apr; 25(1):51. PubMed ID: 38575868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting calcitonin gene-related peptide: a new era in migraine therapy.
    Charles A; Pozo-Rosich P
    Lancet; 2019 Nov; 394(10210):1765-1774. PubMed ID: 31668411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials.
    Silvestro M; Orologio I; Siciliano M; Trojsi F; Tessitore A; Tedeschi G; Russo A
    Expert Opin Emerg Drugs; 2023 Dec; 28(2):79-96. PubMed ID: 37185047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update.
    Charles AC; Digre KB; Goadsby PJ; Robbins MS; Hershey A;
    Headache; 2024 Apr; 64(4):333-341. PubMed ID: 38466028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Medications for the Treatment of Migraine.
    Ceriani CEJ; Wilhour DA; Silberstein SD
    Headache; 2019 Oct; 59(9):1597-1608. PubMed ID: 31559638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
    Yuan H; Spare NM; Silberstein SD
    Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Migraine therapeutics differentially modulate the CGRP pathway.
    Bhakta M; Vuong T; Taura T; Wilson DS; Stratton JR; Mackenzie KD
    Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are antimigraine drugs that influence CGRP levels justified?
    Piechal A; Domitrz I; Kurkowska-Jastrzębska I; Mirowska-Guzel D
    Pharmacol Rep; 2019 Aug; 71(4):624-635. PubMed ID: 31181379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erenumab in the treatment of migraine.
    Jain S; Yuan H; Spare N; Silberstein SD
    Pain Manag; 2018 Nov; 8(6):415-426. PubMed ID: 30235976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mode and site of action of therapies targeting CGRP signaling.
    Labastida-Ramírez A; Caronna E; Gollion C; Stanyer E; Dapkute A; Braniste D; Naghshineh H; Meksa L; Chkhitunidze N; Gudadze T; Pozo-Rosich P; Burstein R; Hoffmann J
    J Headache Pain; 2023 Sep; 24(1):125. PubMed ID: 37691118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in targeting calcitonin gene-related peptide for the treatment of menstrual migraine: A narrative review.
    Jiang Y; Huang ZL
    Medicine (Baltimore); 2022 Jun; 101(24):e29361. PubMed ID: 35713436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gepants - a long way to cure: a narrative review.
    Altamura C; Brunelli N; Marcosano M; Fofi L; Vernieri F
    Neurol Sci; 2022 Sep; 43(9):5697-5708. PubMed ID: 35650458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.